Everence Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Everence Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$403K	Buy	5,413 +243	+5%	+$17K	0.02%	506
2026 Q1	$384K	Hold	5,170	–	–	0.02%	468
2025 Q4	$395K	Hold	5,170	–	–	0.02%	474
2025 Q3	$269K	Hold	5,170	–	–	0.02%	650
2025 Q2	$223K	Buy	+5,170	New	+$188K	0.01%	714

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Everence Capital Management's BBIO Position: Q2 2026 in Review

Everence Capital Management increased its BridgeBio Pharma (BBIO) stake by 4.7% in Q2 2026, buying an estimated $17K and bringing the position to 5,413 shares worth $403K. The position accounts for 0.02% of the portfolio, ranked #506.

Everence Capital Management first reported a position in BBIO in Q2 2025 and has held it in 5 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Everence Capital Management held 5,413 shares of BridgeBio Pharma worth $403K as of Q2 2026.
Everence Capital Management bought 243 BridgeBio Pharma shares in Q2 2026, an estimated $17K.
BridgeBio Pharma made up 0.02% of Everence Capital Management's portfolio in Q2 2026, its #506 holding.
Everence Capital Management first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 5 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.